The availability of a microemulsion formulation (ME) of @entity205 (CyA) displays improved bioavailability and reduced inter and intra- @entity1 variability, resulting in improved long-term outcomes. Recent developments in therapeutic drug monitoring stress the need to optimize peak drug levels during the early posttransplant period to obtain long-term benefit. METHODS: We studied early CyA-ME pharmacokinetics, comparing pre- versus immediate posttransplant values, to assess predictability of pre-transplant profiles in 22 @entity1 including 3 @entity6 . An 8 mg/kg per day amount in two divided doses was administered, for 5 days pretransplant and 10-14 days posttransplant before performing the pharmacokinetic studies. Drugs interacting with CyA metabolism/absorption were withdrawn and @entity1 with @entity409 were excluded the CyA level monitoring used a 5-point blood sampling (at 0 hours, 1 hours, 2 hours, 3 hours, and 4 hours post-dose). The study compared actual concentrations at each individual time and the limited 0-4 hour AUC. RESULTS: The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively. The C1 and C2 values were significantly higher posttransplant (P =.008 and 0.0045 respectively), suggesting a steeper absorption phase, a conclusion consistent with the higher 0-4 hour AUC posttransplant (P =.0089). However, linear regression analysis of pre- versus posttransplant values showed poor correlations. CONCLUSIONS: CyA absorption is significantly lower among @entity1 on maintenance hemodialysis and showed no predictive correlation with posttransplant levels. The possible role of @entity5507 in retarding absorption which may have clinical significance for primary @entity813 , needs further evaluation.

Pre- and postrenal transplantation pharmacokinetics of XXXX microemulsion.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics'] @entity5507 :: ('MESH:D014511', 'Disease') :: ['uremia'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin'] @entity813 :: ('MESH:D055031', 'Disease') :: ['graft dysfunction']
@entity205 :: (MESH:D016572,Chemical) :: ['cyclosporine']
